Detailed data for Pfizer, Lilly anti-NGF mAb highlighted at ACR/ARHP

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) reported detailed efficacy data from the Phase III A4091056 trial evaluating tanezumab compared with placebo to treat osteoarthritis pain. The data showed tanezumab led to significant placebo-adjusted improvements in pain and function of up to 0.8 and 0.9 points, respectively.

Pfizer and Lilly are developing tanezumab as a non-opioid treatment

Read the full 596 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE